All In Biotech

Drug Trial Radar · NCT01033071

Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.

A Phase 3b, Double-Blind, Randomized, 12-Week Efficacy and Safety Study Comparing the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs Olmesartan Medoxomil-Hydrochlorothiazide in Subjects With Moderate to Severe Hypertension

Last checked: Nov 19, 2026Latest source record: Feb 7, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,071 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,071

Actual

Start

Jan 2010

Primary completion

Oct 2010

Study completion Nov 2010

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Dec 16, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the antihypertensive effect of azilsartan medoxomil plus chlorthalidone, once daily (QD), to olmesartan medoxomil plus hydrochlorothiazide in participants with moderate to severe hypertension.

Conditions

  • Essential Hypertension

Interventions

  • Azilsartan medoxomil and chlorthalidoneDrug

    Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks. Participants will be force titrated at Week 4 to azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks. Participants will then be force titrated at Week 8 to azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks.

  • Azilsartan medoxomil and chlorthalidoneDrug

    Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks. Participants will be force titrated at Week 4 to azilsartan medoxomil 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks. Participants will then be force titrated at Week 8 to azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks.

  • Olmesartan medoxomil and hydrochlorothiazideDrug

    Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily and azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for up to 4 weeks. Participants will be force titrated at Week 4 to olmesartan medoxomil 40 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily for the next 4 weeks. Participants will then be force titrated at Week 8 to olmesartan medoxomil 40 mg and hydrochlorothiazide 25 mg combination tablets, orally, once daily for the next 4 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure.Time frame: Baseline and Week 12.

Locations

94 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Gulf Shores, Alabama

  • Site not named

    Litchfield Park, Arizona

  • Site not named

    Mesa, Arizona

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Buena Park, California

  • Site not named

    Carmichael, California

  • Site not named

    Greenbrae, California

  • Site not named

    Irvine, California

  • Site not named

    Paramount, California

  • Site not named

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    San Francisco, California

  • Site not named

    Spring Valley, California

  • Site not named

    Wildomar, California

  • Site not named

    Colorado Springs, Colorado

  • Site not named

    Milford, Connecticut

  • Site not named

    Waterbury, Connecticut

  • Site not named

    Newark, Delaware

  • Site not named

    Aventura, Florida

  • Site not named

    Clearwater, Florida

  • Site not named

    DeLand, Florida

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Ocala, Florida

  • Site not named

    Plant City, Florida

  • Site not named

    Tallahassee, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    West Palm Beach, Florida

  • Site not named

    Winter Haven, Florida

  • Site not named

    Dunwoody, Georgia

  • Site not named

    Roswell, Georgia

  • Site not named

    Suwanee, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Melrose Park, Illinois

  • Site not named

    Naperville, Illinois

  • Site not named

    Avon, Indiana

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Valparaiso, Indiana

  • Site not named

    Crestview Hills, Kentucky

Showing 40 of 94 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.